Opinion Article - Journal of Clinical Research and Pharmacy (2023) Volume 6, Issue 1

Comparison of abiraterone′s with enzalutamide′s patient safety and efficacy results

Abiraterone and enzalutamide are two oral medications used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study aims to compare the patient safety and efficacy results of these two drugs. A systematic review and meta-analysis were conducted using randomized controlled trials that compared abiraterone and enzalutamide in mCRPC patients. The safety outcomes assessed were overall adverse events, serious adverse events, and treatment discontinuation due to adverse events. The efficacy outcomes assessed were overall survival, radiographic progression-free survival, and prostate-specific antigen (PSA) response. The results showed that both drugs were generally safe and well-tolerated. In abiraterone and enzalutamide have similar efficacy outcomes in mCRPC patients, but abiraterone may have a better safety profile with lower rates of serious adverse events and treatment discontinuation due to adverse events. These findings may aid in the decision-making process when selecting treatment options for mCRPC patients.

Author(s): Sudhansu Sekhar Patra

Abstract Full Text PDF